Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01579916 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
A Phase 4 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 4
- Development phase
- 303
- Enrollment target
NCT01579916 is a Phase 4 study that has completed, run by MedImmune. The registered enrollment target is 303 participants.
The verdict
NCT01579916, a Phase 4 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 303 participants
- Enrollment target
Study Summary
This prospective annual release study was designed to assess the safety of a trivalent influenza virus vaccine using two new strains recommended for the 2012-2013 influenza season not previously contained in the trivalent intranasal FluMist vaccine. Three hundred healthy adults will receive a single dose of vaccine or placebo and will be followed for 180 days after study vaccination.
Interventions
- OTHER Placebo
- BIOLOGICAL Trivalent Influenza Virus Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2012-05 |
| Est. Completion | 2012-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01579916
The ClinicalTrials.gov registry entry for NCT01579916 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 303 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01579916 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01579916 about?
NCT01579916 is a clinical study titled "A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults". This prospective annual release study was designed to assess the safety of a trivalent influenza virus vaccine using two new strains recommended for the 2012-2013 influenza season not previously contained in the trivalent intranasal FluMist vaccine. Three hundred healthy adults will receive a singl...
What is the current status of trial NCT01579916?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 303 participants. The study started on 2012-05. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01579916?
The interventions under investigation include: Placebo (OTHER), Trivalent Influenza Virus Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01579916?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.